273 related articles for article (PubMed ID: 32324179)
21. Pitavastatin magnesium (Zypitamag) for hyperlipidemia.
Med Lett Drugs Ther; 2018 Jun; 60(1549):106. PubMed ID: 29913475
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
23. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
25. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
Burke AC; Telford DE; Huff MW
Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
27. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
Nguyen H; Akamnonu I; Yang T
Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
[TBL] [Abstract][Full Text] [Related]
28. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
[TBL] [Abstract][Full Text] [Related]
29. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
[TBL] [Abstract][Full Text] [Related]
31. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
33. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
[TBL] [Abstract][Full Text] [Related]
35. Bempedoic Acid: First Approval.
Markham A
Drugs; 2020 May; 80(7):747-753. PubMed ID: 32314225
[TBL] [Abstract][Full Text] [Related]
36. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
37. Evaluating bempedoic acid for the treatment of hyperlipidaemia.
Penson P; McGowan M; Banach M
Expert Opin Investig Drugs; 2017 Feb; 26(2):251-259. PubMed ID: 28064554
[TBL] [Abstract][Full Text] [Related]
38. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
39. Targeting low-density lipoprotein and dysmetabolism in type 2 diabetes mellitus.
Goldberg R
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):477-8. PubMed ID: 24554605
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis.
Wang X; Zhang Y; Tan H; Wang P; Zha X; Chong W; Zhou L; Fang F
Cardiovasc Diabetol; 2020 Aug; 19(1):128. PubMed ID: 32787939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]